A world-first randomised controlled trial shows daily statin therapy cuts the risk of a first major cardiovascular event by 30% in adults aged over 70. Led by Monash University and presented at the European Society of Cardiology Congress, the STAREE trial provides vital primary prevention data for older populations.
Understanding the STAREE Trial and Cardiovascular Primary Prevention
Cardiovascular disease remains a major concern for older people. For years, clinicians lacked robust, direct randomised evidence to guide primary prevention—protecting patients who have never experienced a heart attack or stroke—specifically within the over-70 cohort. The STAREE trial directly addressed this clinical gap. Enrolling nearly 10,000 participants aged 70 and older with a mean age of approximately 75 years, the double-blind, placebo-controlled study evaluated whether daily statin administration safely prevents initial major vascular events.
By inhibiting a specific hepatic enzyme responsible for cholesterol synthesis, these lipid-lowering drugs known as statins effectively decrease cholesterol levels. Through lowering low-density lipoprotein (LDL) cholesterol—frequently referred to as “bad” cholesterol—statins assist in stopping the accumulation of fatty substances inside artery walls that can cause strokes and heart attacks. The trial demonstrated a striking number needed to treat: just 37 older adults need to be treated with daily statins over roughly six years to prevent one major cardiac event, such as a heart attack, stroke, or heart surgery.
In Plain English: The Clinical Takeaway
- What was found: Daily statin use lowers the risk of a first heart attack or stroke by 30% in adults over 70, with a low risk of serious side effects.
- What it means: For every 37 people in their mid-70s taking a daily statin for about six years, one serious heart event is successfully averted.
- Next steps: Older adults can now use these findings to have informed, evidence-based conversations with their general practitioners regarding personalised cardiovascular health plans.
Global Research Collaboration and Regulatory Implications
The trial’s design relied heavily on community-based integration, drawing participation from nearly 3,400 general practitioners across Australia. Lead researcher Adjunct Professor Sophia Zoungas from Monash University’s School of Public Health and Preventive Medicine noted that solid evidence for safe, effective risk reduction offers substantial reassurance to older individuals and their families. Co-author Adjunct Professor Mark Nelson emphasised that this community-based model ensures the findings translate directly into everyday primary care practice. The study validates that statins retain their therapeutic value even when treatment begins later in life, a point underscored by Professor Derek Chew, Chief Scientific and Medical Officer at the National Heart Foundation of Australia, an organization that provided funding support for the investigation.
These findings arrive alongside prior supportive data. A 2019 meta-analysis by the Cholesterol Treatment Trialists’ Collaboration established that statin therapy reduces major vascular events across all age groups, including individuals over 75, though direct randomised proof in the over-70 primary prevention demographic was previously thin. Researchers hope this new data will prompt updated treatment guidelines so clinicians can properly apply this new evidence in practice.
| Metric | Trial Data / Finding |
|---|---|
| Study Design | Randomised, double-blind, placebo-controlled trial |
| Participant Age | Mean age approximately 75 years (enrolling adults aged 70+) |
| Risk Reduction | 30% reduction in first major cardiovascular events |
| Number Needed to Treat (NNT) | 37 older adults treated for nearly 6 years to prevent one major event |
| GP Involvement | Nearly 3,400 general practitioners participating across Australia |
When to Consult a Doctor
Older individuals should never alter their medication regimen or initiate new drug therapies without professional medical supervision. Schedule an appointment with your primary care physician or general practitioner to review your individual circumstances.
Future Outlook and Preventive Longevity
As global populations age at unprecedented rates, answering fundamental questions about healthy longevity has become a genuinely universal priority. The STAREE trial establishes a benchmark for international clinical research, demonstrating that primary prevention in older cohorts is both viable and efficacious. As medical guidelines adapt to incorporate these findings, clinicians are better equipped to balance pharmacological efficacy against individual patient profiles, ensuring optimal cardiovascular health outcomes well into later life.
References
- Cholesterol Treatment Trialists’ Collaboration, 2019.
- Monash University School of Public Health and Preventive Medicine. STAREE Trial Results and Protocol Publications.
- European Society of Cardiology. Annual Congress Clinical Trial Presentations.
Disclaimer: This article reports on published research and is general in nature. Consult your general practitioner to discuss whether statin treatment fits your personal health needs, as this information does not constitute tailored medical guidance.
Related reading
